Circulating interleukin 1 beta and soluble interleukin 2 receptor: evaluation as markers of disease activity in scleroderma

J Rheumatol. 1995 Apr;22(4):654-8.

Abstract

Objectives: To investigate whether circulating levels of interleukin 1 beta (IL-1 beta) or soluble interleukin 2 receptor (sIL-2R) reflect clinical disease status and response to therapy in scleroderma.

Methods: Plasma IL-1 beta and serum sIL-2R were measured by ELISA in 19 patients with limited cutaneous scleroderma (9 with extraesophageal internal organ involvement), 5 patients with diffuse cutaneous scleroderma and internal organ involvement, and 11 healthy controls, as well as serially over 12 months in 4 patients with scleroderma treated with cyclosporine.

Results: IL-1 beta levels were similar in scleroderma and control subject groups. sIL-2R levels were significantly higher in subjects with scleroderma involving internal organs (elevated in 93%), and correlated with erythrocyte sedimentation rate. sIL-2R levels decreased over 12 months in 2 of 4 patients taking cyclosporine in whom other variables remained unchanged.

Conclusions: Elevated serum sIL-2R is a marker of internal organ involvement in scleroderma and warrants further investigation in assessing disease prognosis and response to therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Sedimentation
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Interleukin-1 / blood*
  • Male
  • Middle Aged
  • Receptors, Interleukin-2 / metabolism*
  • Scleroderma, Localized / blood
  • Scleroderma, Localized / drug therapy
  • Scleroderma, Localized / physiopathology
  • Scleroderma, Systemic / blood*
  • Scleroderma, Systemic / drug therapy
  • Scleroderma, Systemic / physiopathology
  • Solubility

Substances

  • Interleukin-1
  • Receptors, Interleukin-2
  • Cyclosporine